Skip to content

Clinical trials

Adenoma, Islet Cell trials

Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.

Filters: Condition: Adenoma, Islet Cell Clear all

113 trials match Source: ClinicalTrials.gov registrations

Trials started per year

By phase, 2000 to 2026.

Trials started per year
CategoryTrials
20002
20012
20021
20031
20041
20052
20062
20072
20086
20093
20102
20113
20124
20133
20144
20157
20161
20173
20187
20198
20201
20213
20229
20237
202410
20255
20266

Status

Trials by registry status. Select a bar to filter.

Trials by status
CategoryTrials
Completed43
Recruiting22
Unknown status18
Active, not recruiting12
Terminated9
Withdrawn2
Enrolling by invitation2
Not yet recruiting2
Suspended1
No longer available1
Available1

Top lead sponsors

A sponsor with a page on Pharma Observatory links to it.

Top lead sponsors
CategoryTrials
Dana-Farber Cancer Institute5
Fudan University5
National Cancer Institute (NCI)4
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)3
Changhai Hospital2
European Institute of Oncology2
Guangxi Medical University2
H. Lee Moffitt Cancer Center and Research Institute2
Institut Paoli-Calmettes2
M.D. Anderson Cancer Center2

Top conditions

MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.

Top conditions
CategoryTrials
Adenoma, Islet Cell113
Neuroendocrine Tumors29
Pancreatic Neoplasms20
Insulinoma17
Somatostatinoma16
Carcinoid Tumor15
Carcinoma, Islet Cell14
Gastrinoma14
Neoplasms14
Glucagonoma13

Trials

Showing 26 to 50 of 113. Each trial links to its page on Pharma Observatory.

13 more trials match. See them on Pharma Observatory

Recently changed trials

Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.

No changes to these trials in the last 7 days.

Go deeper on Pharma Observatory

Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.